Helsinn Group

Evolving data on new antibody-drug conjugates (ADCs) suggests that some may cause nausea and vomiting lasting more than 5 days (referred to as “long-delayed CINV”). Administering guideline-recommended antiemetic prophylaxis is critical, especially considering the extended treatment duration for many patients. As uncontrolled CINV significantly increases the risk for CINV in subsequent cycles, appropriate upfront antiemetics when initiating ADCs are essential to optimize patient outcomes. #seeCINVbetter #supportivecare #ADCs         

We are pleased to announce that AKYNZEO® injection (fosnetupitant/palonosetron) is now available in the US in a ready-to-use vial. Dr. Melanie Rolli expresses her insights on this significant milestone. To find out more, read the full announcement here: https://lnkd.in/dnapPdkW #supportivecare

Our technical organization orchestrates a balanced mix of internal and external capabilities also for manufacturing and supply chain. At our state-of-the-art manufacturing facility in Ireland, we manufacture commercial solid and semisolid dosage forms and handle high-potency drugs. Analytical testing and QP release are run on site, as is the management of the global supply chain that reaches patients all around the globe. Learn more about our journey to in-house product manufacturing and supply: https://lnkd.in/ekCtvEJp #manufacturing

This is the future vision for Helsinn Group as explained by our #CEO Dr. Melanie Rolli. #transformation

Today, we have the opportunity to be on the ground and connect with the healthcare community at the MASCC Annual Meeting in Paris. We have the chance to explore the latest advances in #supportivecare to reinforce our commitment to improving patients' quality of life.   #MASCC24

Helsinn is committed to raising awareness of the importance of antiemetic guidelines. In synch with the #MASCC24 annual meeting, Helsinn reminds HCPs that MASCC/ESMO released new antiemetic guidelines. Key practice changing updates include recommended use of a triple combination of a NK1 receptor antagonist (RA), 5-HT3 RA and steroids prophylactically in situations where emetogenic potential is now considered at the high end of the moderate category (eg, for patients receiving carboplatin (AUC ≥ 5), for women <50 receiving oxaliplatin, for patients receiving ADCs such as trastuzumab-deruxtecan and sacituzumab-govitecan). #supportivecare #antiemetics #CINV

  Today marks the start of World Wellbeing Week! At Helsinn, we place a high value on the health and happiness of our employees. Take for instance, at Helsinn Birex Pharmaceuticals Ltd, Dublin, the annual employee wellbeing plans are holistically designed to enhance the health and wellness of all, with topics and initiatives as diverse as the employees to which they serve.  At the core of our wellness programme is health screening. Each year our employees in Ireland undergo a full medical screening and have the added options of attending onsite pop-up clinics that deliver flu vaccinations and a range of cancer and heart screening services. The 2024 Wellbeing Programme also allows employees to sign up for physical activities such as onsite Pilates classes, reflexology, massage and physiotherapy sessions. Employees can engage in financial health consultations with pension providers, mortgage lenders and personal taxes and attend onsite seminars in a range of topics related to mental health. #wellbeing

We are delighted to announce the renewal of our commercial agreement with Chugai Pharma Europe to continue supporting patients with chemotherapy-induced nausea and vomiting (CINV) in the UK and Ireland. Dr. Melanie Rolli, Helsinn Group Chief Executive Officer, offers her perspective on this important agreement. Read the full press release here: https://lnkd.in/dYpFBXdF #supportivecare  #partnering

Representatives from our company recently had the privilege of participating in a marketing meeting in Italy with our esteemed business partners, the Helsinn Group. This remarkable event gathered colleagues from over 20 countries, all united by a common goal: enhancing strategies and activities to combat chemotherapy-induced nausea and vomiting (CINV). Together, Helsinn and Rafa are committed to raising the bar of CINV prevention, the meeting was an invaluable opportunity to gain insights from diverse global perspectives, understand the unique challenges and solutions each country faces, and present our latest strategies and best practices. We extend our gratitude to Helsinn for hosting such a professional and enriching event, and for their generous Italian hospitality.

We are pleased to celebrate #WorldEnvironmentDay. This is the largest global day for the environment, calling for collective, transformative action on a global scale to celebrate, protect and restore our planet. At Helsinn, we are committed to preserving our environment for future generations and have implemented lasting and sustainable solutions to help address the climate crisis. We are a Carbon Neutral company since 2021 and have been on a decarbonization path since 2015. In our Swiss and Irish companies, we use only renewable electricity, and we have installed solar panels and electric vehicle charging stations.   We have signed an agreement with the Swiss Federal Office for Energy to design a decarbonization path that will lead to Helsinn becoming a Net-Zero company in the long term.   To learn more about our environmental performance: https://lnkd.in/dhfYtigK   #generationrestoration #sustainability